

MolMed Shareholders' Meeting approves:

- *the Financial Statements as at 31 December 2014 and resolved to carry forward the loss of € 13.0 million;*
- *the first section of the report on remuneration, pursuant to art. 123-ter, paragraph 6, of the Legislative Decree 58/98 as amended ("TUF");*
- *the reduction of the number of the members of the Board of Directors to 11;*
- *the deferral of the re-determination of the compensation of the administrative body.*

Milan (Italy), 3 June 2015 – The Shareholders' Meeting of MolMed S.p.A. (MLM.MI), chaired by Professor Claudio Bordignon, met today to resolve upon the items of the agenda:

Approval of the Statutory Financial Statements for year 2014

The Meeting approved the Statutory Financial Statements for FY ended 31 December 2014, and resolved to carry forward the loss of € 13.0 million. The approved Statutory Financial Statements reported a loss in line with expectations for the period and reflects the business model of a biotech company focused on R&D activities whose economic returns are deferred to future years. The approved Financial Statements reported a positive net financial position of € 11.4 million, consisting of cash free of financial indebtedness.

Report on Remuneration

The Meeting resolved to express a favourable advisory opinion on the contents of Section I of the Report on Remuneration in accordance with art. 123-ter TUF.

Reduction of the number of the members of the Board of Directors to 11

After the resignation of Director Riccardo Cortese, the Board of Directors decided not to replace him immediately by cooptation, believing that it would be correct to put every decision to the Shareholders' Meeting.

The Shareholders' Meeting resolved to reduce from 12 to 11 the numbers of the Board of Directors, also taking into account that the Board of Directors has the necessary and appropriate professional skills for the management of the Company, also taking into account the suggestions expressed in recent reports on corporate governance on Board composition.

Re-determination of compensation of the administrative body

The Meeting approved the proposal to defer every resolution concerning the re-determination of compensation of the administrative body.

FROM GENES TO THERAPY

MOLMED S.p.A.

Via Olgettina, 58 - 20132 Milan, Italy | Phone +39 02 21277.1 - Fax +39 02 21277.325
info@molmed.com - www.molmed.com

Share capital € 19,841,682.30 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159

In accordance with the provisions of art. 125-quater, paragraph 2, of the TUF and art. 77, paragraph 3, of the Issuers' Regulations a summary report containing the number of voting shares represented at the meeting and the actions for which the vote was cast, the percentage of capital that these shares represent, as well as the number of votes for and against the resolutions and the number of abstentions, will be made available to the public within five days from the date of the Shareholders' meeting on the Company's website.

The minutes of the Shareholders' Meeting will be made available to the public within the terms provided by the laws and regulations in force.

The official manager responsible for preparing the Company's financial reports, Andrea Quaglino, herewith attests, pursuant to Article 154-bis, paragraph 2 of the Italian Consolidated Law on Finance (Legislative Decree 58/1998, as amended), that the accounting disclosure contained in this press release matches documentary evidence, corporate books, and accounting records.

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14 May 1999, as subsequently amended.

About MolMed

MolMed S.p.A. is a biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed's pipeline includes two antitumour therapeutics in clinical development: TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression, in Phase III in high-risk acute leukaemia; NGR-hTNF, a novel vascular targeting agent, in Phase III in malignant pleural mesothelioma and in Phase II in six more indications: colorectal, lung (small-cell and non-small-cell), liver and ovarian cancer, and soft tissue sarcomas. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy. The Company's shares are listed on the main market (MTA) of the Milan Stock Exchange. (Ticker Reuters: MLMD.MI)

For further information:

Marina Del Bue

General Manager Corporate Governance & Administration

Investor Relations Director *ad int.*

MolMed S.p.A.

phone: +39 02 21277.411

fax: +39 02 21277.325

e-mail: investor.relations@molmed.com



PRESS RELEASE

Press agent

Federico Ferrari

SEC Relazioni Pubbliche e Istituzionali srl

phone: +39 02 6249991 – mobile +39 347 6456873

e-mail: ferrari@secrp.it

DISCLAIMER

This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A.